Hereditary Breast and Ovarian Cancer Molecular Mechanism and Clinical Practice

1 History, Advancements, and Future Strategies.- 2 Molecular basis of BRCA1 and BRCA2 - Homologous recombination deficiency and tissue-specific carcinogenesis.- 3 Genetic Testing.- 4 Variants of uncertain significances in hereditary breast and ovarian cancer.- 5 Genetic counseling in Hereditary Breast and Ovarian Cancer.- 6 Hereditary Breast Cancer.- 7 Hereditary Ovarian Cancer.- 8 Risk-Based Breast Cancer Screening.- 9 Chemoprevention for Breast Cancer.- 10 Chemoprevention for Ovarian Cancer.- 11 Risk-Reducing Mastectomy (RRM).- 12 Risk-reducing salpingo-oophorectomy (RRSO).- 13 Panel Testing.- 14 Germline Findings through Precision Oncology for Ovarian Cancer.- 15 Germline Findings from Genetic Testing for Breast Cancer.- 16 Hereditary Breast and Ovarian Cancer (HBOC) Database.- 17 Ethical Issues: Overview in Genomic analysis and Clinical Context.- 18 PARP Inhibitors-Mechanism of action.- 19 PARPi - Efficacy in Hereditary Breast Cancer.- 20 Efficacy of Poly ADP-Ribose Polymerase Inhibitors for Hereditary Ovarian Cancer.

Department of Breast Surgical Oncology

Showa University, School of Medicine

Tokyo, Japan

Daisuke Aoki

Department of Obstetrics and Gynecology,

Keio University School of Medicine,

Tokyo, Japan

Yoshio Miki

Department of Molecular Genetics, Medical Research Institute,

Tokyo Medical and Dental University,

Tokyo, Japan